Track topics on Twitter Track topics that are important to you
Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia articles that have been published worldwide.
We have published hundreds of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia news stories on BioPortfolio along with dozens of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Clinical Trials and PubMed Articles about Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Companies in our database. You can also find out about relevant Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Drugs and Medications on this site too.
EPH receptors are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates the intracellular kinase activity. EPHs are key players in bidirectional intercellular signaling, controlling cell morphology, adhesion and migration. They are increasingly recognized as cancer drug targets. We analyzed the binding of the Novartis inhibitor NVP-BHG712 (NVP) to EPHA2 and EPHB4. Unexpectedly, all tested commercially available NVP samples tu...
In Kenya, noncommunicable diseases (NCDs) account for 27% of all deaths. Adult Kenyans have an 18% chance of dying prematurely from cancers, diabetes, cardiovascular diseases or chronic respiratory diseases. A Novartis Access Initiative is making medicines available to treat cardiovascular diseases, diabetes, chronic respiratory diseases, and breast cancer in 30 countries, including Kenya. Little is known about patients' perceptions of access to medicines for NCDs in Kenya. The study objective was to unders...
Clinicians working on first-in-human clinical studies need to be able to judge whether safety signals observed on an investigational drug were more likely to have occurred by chance or to have been caused by the drug. We retrospectively reviewed 84 Novartis studies including 1,234 healthy volunteers receiving placebo to determine the expected incidence of changes in commonly measured laboratory parameters and vital signs, in the absence of any active agent. We calculated the frequency of random incidence of...
T cells that are genetically modified to express chimeric antigen receptors (CARs) specific for CD19 show great promise for the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL). The first FDA approval of a cellular cancer therapy in 2017, i.e. Novartis' CD19-targeting CAR T cell product Kymriah™ within the context of relapsed/refractory paediatric ALL, followed rapidly by approval of Kite's Yescarta™ and more recently, Kymriah™ for diffuse large B cell indications in adults, highli...
Metabotropic glutamate receptor 5 (mGluR) is a drug target for central nervous system disorders such as fragile X syndrome that involve excessive glutamate-induced excitation. We tested the efficacy of a novel negative allosteric modulator of mGluR developed by Merz Pharmaceuticals, MRZ-8456, in comparison to MPEP and AFQ-056 (Novartis, a.k.a. mavoglurant) in both in vivo and in vitro assays in a mouse model of fragile X syndrome, Fmr1 mice. The in vivo assays included susceptibility to audiogenic-induced s...
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
The National Institute for Health and Care Excellence, as part of the institute's single technology appraisal process, invited the manufacturer of ribociclib (Kisqali, Novartis) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer. Kleijnen Systematic Reviews Ltd and Erasmus Uni...